Gaining trust has a significant effect on disease management and patient care, according to experts at ACR Convergence 2023. Here are insights into the barriers to that trust and how healthcare providers can develop trusting relationships with their patients.
2023 marks the post-pandemic return of research exchanges hosted by the ACR & EULAR to benefit junior academic rheumatologists & rheumatology professionals.
How can we ensure patients are receiving care that addresses all of the ways rheumatic disease affects their life? In this ACR Convergence 2023 session, experts discuss the value of a strong interprofessional care team.
In this ACR Convergence 2023 session, experts offered guidance on a selection of diagnostic & treatment challenges rheumatologists may encounter.
SAN DIEGO—During ACR Convergence 2023 in November, the ACR and the ARP honored a group of distinguished individuals who have made significant contributions to rheumatology research, education and patient care. This month, The Rheumatologist profiles the recipients of the ARP President’s Awards. The ARP president can choose to honor ACR/ARP members or teams performing outstanding…
During ACR Convergence 2023, experts discussed developments in the treatment and diagnosis of osteoporosis, addressing risks of treatment discontinuation, the use of bone turnover markers in patient assessment and vitamin D.
Pain management can involve more than active pharmacologic treatment. During a session at ACR Convergence 2023, experts addressed the benefits of patient self-management for pain, how it works with clinical care and the role of technology.
Lifestyle medicine interventions, such as dietary changes, movement and mindfulness, in combination with conventional treatment, may help alleviate symptoms of rheumatic disease, according to panelists at ACR Convergence 2023.
Originally posted Feb. 13, 2023; reposted in conjunction with publication of the PMR supplement to the February 2024 issue of The Rheumatologist. PHILADELPHIA—Polymyalgia rheumatica (PMR) is a chronic inflammatory condition that almost exclusively affects individuals older than 50.1 First described in 1888, PMR has been a recognized rheumatic disease since at least 1957. Diagnosing the…
What Are the Therapeutic Alternatives When a Janus Kinase Inhibitor Fails to Work? SAN DIEGO—Treatment alternatives after Janus kinase (JAK) inhibitor failure in real-life conditions were analyzed and presented at ACR Convergence 2023 by Pablo Francisco Muñoz Martínez, a rheumatologist at the Hospital Universitario y Politécnico La Fe, Sagunto, Spain.1 JAK inhibitors are newer, targeted…